Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Divestments (2022 - 2023)

Marker Therapeutics (MRKR) has disclosed Divestments for 2 consecutive years, with $18.8 million as the latest value for Q2 2023.

  • On a quarterly basis, Divestments changed N/A to $18.8 million in Q2 2023 year-over-year; TTM through Dec 2023 was $18.7 million, a N/A change, with the full-year FY2023 number at $18.7 million, up 477.42% from a year prior.
  • Divestments was $18.8 million for Q2 2023 at Marker Therapeutics, up from -$112608.0 in the prior quarter.
  • In the past five years, Divestments ranged from a high of $18.8 million in Q2 2023 to a low of -$127342.0 in Q4 2022.